KX01 is an inhaled anti-inflammatory treatment for patients developing chronic lung allograft dysfunction (CLAD) after lung transplant and allogenic stem cell transplant. Currently, no treatments are approved by FDA.
KX01 have showed to address inflammation, fibrosis, and vasculopathy with the potential to prevent and treat chronic lung allograft dysfunction in lung transplantation patients.
Reducing disease burden for Lung Transplant patients
KX01 is an inhaled treatment for lung transplant patients.
KX01 has the potential to reduce disease burden and improve quality of life in patients with CLAD.